ClinicalTrials.gg

Program

ATH434

Also written as “ATH434 dose level 1” and “ATH434 dose level 2”.

Its studies are mostly in Multiple System Atrophy, led by Alterity Therapeutics.

Furthest: phase 2, since Oct 22, 20213 company-led studies, 1 open or runningNext primary completion: Jul 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alterity Therapeutics31 open or runningphase 2since Oct 22, 2021Oct 22, 2021Jul 2029phase 2 · NCT07729852

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2021First study: phase 2 study in Multiple System AtrophyFirst studyNCT05109091 · 77 enrolled · United States, Australia, France and more
  2. May 9, 2023Phase 2 study in Multiple System AtrophyNCT05864365 · 10 enrolled · United States
  3. Jul 16, 2026Phase 2 study in Multiple System AtrophyNCT07729852 · 7 planned · France

Ahead

  1. Jul 2029Primary completion: phase 2 study in Multiple System AtrophyNCT07729852

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07729852Multiple System Atrophy · France2By invitationJul 20297
NCT05864365Multiple System Atrophy · United States2CompletedFeb 26, 202510
NCT05109091Multiple System Atrophy · United States, Australia, France and more2CompletedNov 28, 202477

How it is read

Names in the registry

  • “ATH434”, 2 entries
  • “ATH434 dose level 1”, 1 entry
  • “ATH434 dose level 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.